An update on NIH RECOVER-TLC (Treating Long COVID) trials, reporting that the REVERSE-LC trial testing baricitinib is actively enrolling at 17 U.S. sites, and that three more trials testing low-dose naltrexone, semaglutide, and stellate ganglion block are expected to begin enrolling later in the year.